**Table 2:** Cox-regression on overall survival

|  |  |  |  |
| --- | --- | --- | --- |
|   | **All stages** | **cT2 cN0/X** | **cT3-4 cN0/X** |
|   | **HR** | **95% CI** | **P-value** | **HR** | **95% CI** | **P-value** | **HR** | **95% CI** | **P-value** |
| **Model 1\*** |  |  |  |  |  |  |  |  |  |
| **DUOS Center** |   |   |   |   |   |   |   |   |   |
| No | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Yes | 0.94 | (0.84 - 1.05) | 0.28 | 0.93 | (0.83 - 1.06) | 0.27 | 0.92 | (0.72 - 1.19) | 0.52 |
| **Model 2\*\*** |  |  |  |  |  |  |  |  |  |
| **DUOS Center** |   |   |   |   |   |   |   |   |   |
| No | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Yes | 0.96 | (0.86 - 1.07) | 0.44 | 0.96 | (0.84 - 1.08) | 0.45 | 0.91 | (0.70 - 1.18) | 0.44 |
| **Model 3\*\*\*** |  |  |  |  |  |  |  |  |  |
| **DUOS Center** |   |   |   |   |   |   |   |   |   |
| No | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Yes | 0.96 | (0.86 - 1.07) | 0.45 | 0.96 | (0.85 - 1.08) | 0.45 | 0.92 | (0.72 - 1.19) | 0.53 |
| **Model 4\*\*\*\*** |  |  |  |  |  |  |  |  |  |
| **DUOS Center** |   |   |   |   |   |   |   |   |   |
| No | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Yes | 0.94 | (0.84 - 1.05) | 0.27 | 0.93 | (0.82 - 1.06) | 0.27 | 0.97 | (0.74 - 1.26) | 0.81 |
| **Neo-adjuvant chemotherapy** |   |   |   |   |   |   |   |   |   |
| No | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Yes | 0.98 | (0.81 - 1.18) | 0.80 | 1.05 | (0.83 - 1.33) | 0.70 | 0.72 | (0.53 - 0.99) | 0.04 |
| **Differentiation grade** |   |   |   |   |   |   |   |   |   |
| Well or moderately differentiated | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Poorly differentiated | 1.06 | (0.86 - 1.31) | 0.61 | 1.03 | (0.82 - 1.31) | 0.78 | 1.18 | (0.69 - 2.03) | 0.55 |
| Unknown | 1.11 | (0.75 - 1.66) | 0.60 | 1.17 | (0.76 - 1.81) | 0.48 | 0.95 | (0.34 - 2.68) | 0.92 |
| **Number of identified LNs** |   |   |   |   |   |   |   |   |   |
| 1-9 | 1.33 | (1.2 - 1.48) | < 0.0001 | 1.32 | (1.17 - 1.49) | < 0.0001 | 1.47 | (1.16 - 1.86) | 0.00 |
| ≥ 10 | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| Number of LN dissected/counted not documented | 1.04 | (0.88 - 1.23) | 0.66 | 1.04 | (0.87 - 1.26) | 0.67 | 1.02 | (0.68 - 1.54) | 0.91 |
| **Number of positive LNs** |   |   |   |   |   |   |   |   |   |
| No positive LNs | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| 1-4 | 2.07 | (1.85 - 2.31) | < 0.0001 | 2.08 | (1.83 - 2.36) | < 0.0001 | 1.87 | (1.47 - 2.38) | < 0.0001 |
| 5-9 | 3.82 | (2.89 - 5.06) | < 0.0001 | 4.21 | (3.02 - 5.87) | < 0.0001 | 2.80 | (1.64 - 4.78) | 0.00 |
| ≥ 10 | 4.06 | (2.19 - 7.55) | < 0.0001 | 5.75 | (2.53 - 13.09) | < 0.0001 | 2.15 | (0.77 - 6.06) | 0.15 |
| Positive LNs, but number unknown | 3.90 | (2.57 - 5.93) | < 0.0001 | 3.43 | (2.06 - 5.73) | < 0.0001 | 4.80 | (2.28 - 10.08) | < 0.0001 |
| **Surgical margins of cystectomy** |   |   |   |   |   |   |   |   |   |
| negative  | 1.00 |   |   | 1.00 |   |   | 1.00 |   |   |
| positive  | 2.51 | (2.14 - 2.94) | < 0.0001 | 2.62 | (2.16 - 3.18) | < 0.0001 | 2.19 | (1.64 - 2.92) | < 0.0001 |
| Unknown | 2.12 | (1.7 - 2.64) | < 0.0001 | 2.16 | (1.68 - 2.76) | < 0.0001 | 2.11 | (1.3 - 3.43) | 0.00 |

**\*Model 1:** Univariate model on effect of being treated in DUOS center vs. not being treated in a DUOS center; **\*\*Model 2:** Multivariable model on effect of being treated in DUOS center vs. not being treated in a DUOS center with correction for patient characteristics (gender, age and period of diagnosis), only the hazard ratio of DUOS center is being showed; **\*\*\*Model 3:** Model 2 + with correction for receiving neo-adjuvant chemotherapy (yes vs. no), only the hazard ratio of DUOS center is being showed; **\*\*\*\*Model 4:** Model 3 + correction for post-operative factors (differentiation grade, number of identified lymph nodes, number of positive lymph nodes, surgical margin of cystectomy.